72nd OREGON LEGISLATIVE ASSEMBLY--2003 Regular Session
 
NOTE:  Matter within  { +  braces and plus signs + } in an
amended section is new. Matter within  { -  braces and minus
signs - } is existing law to be omitted. New sections are within
 { +  braces and plus signs + } .
 
LC 1347
 
                         House Bill 3382
 
Sponsored by Representative GREENLICK; Representatives BATES,
  MONNES ANDERSON
 
 
                             SUMMARY
 
The following summary is not prepared by the sponsors of the
measure and is not a part of the body thereof subject to
consideration by the Legislative Assembly. It is an editor's
brief statement of the essential features of the measure as
introduced.
 
  Directs Oregon Department of Administrative Services to adopt
preferred drug list for state agencies that directly or
indirectly purchase prescription drugs. Directs Office for Oregon
Health Policy and Research to recommend preferred drug list to
department.
 
                        A BILL FOR AN ACT
Relating to prescription drugs.
Be It Enacted by the People of the State of Oregon:
  SECTION 1.  { + (1) The Oregon Department of Administrative
Services shall adopt a preferred drug list for state agencies
that directly or indirectly purchase prescription drugs. The
purpose of the preferred drug list is to maintain a list of
prescription drugs recommended by the Office for Oregon Health
Policy and Research as the most effective prescription drugs
available at the best possible prices.
  (2) The Office for Oregon Health Policy and Research shall
develop and recommend to the Oregon Department of Administrative
Services a preferred drug list for use by state agencies that
directly or indirectly purchase prescription drugs. The office
shall conduct public hearings and use evidence-based evaluations
on the effectiveness of similar prescription drugs to develop the
preferred drug list.
  (3) The use of the preferred drug list is subject to common
methods of managing prescription drug benefits, including but not
limited to prior authorization of non-preferred prescription
drugs, copayments, drug utilization review, disease management
and supplemental rebates from drug manufacturers. + }
                         ----------